HBV cccDNA and Its Potential as a Therapeutic Target
Open Access
- 31 July 2019
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (X), 1-5
- https://doi.org/10.14218/jcth.2018.00054
Abstract
Chronic hepatitis B virus infection continues to be a major health burden worldwide. It can cause various degrees of liver damage and is strongly associated with the development of liver cirrhosis and hepatocellular carcinoma. Covalently closed circular DNA in the nucleus of infected cells cannot be disabled by present therapies which may lead to HBV persistence and relapse. In this review, we summarized the current knowledge on hepatitis B virus covalently closed circular DNA and its potential role as a therapeutic target.Keywords
This publication has 69 references indexed in Scilit:
- Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector NucleasesMolecular Therapy, 2013
- Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cellsNucleic Acids Research, 2012
- RNA-guided genetic silencing systems in bacteria and archaeaNature, 2012
- A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicityNucleic Acids Research, 2011
- Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAsMolecular Therapy, 2010
- Methylation Regulates Hepatitis B Viral Protein ExpressionThe Journal of Infectious Diseases, 2009
- Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene ModificationMolecular Cell, 2008
- Comprehensive Genetic and Epigenetic Analysis of Occult Hepatitis B from Liver Tissue SamplesClinical Infectious Diseases, 2008
- Molecular Virology of Hepatitis B Virus for CliniciansClinics in Liver Disease, 2007
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyGastroenterology, 2004